TScan Therapeutics, Inc. has filed an 8-K report detailing the resignation of Leiden Dworak as Vice President of Finance and principal accounting officer, effective April 10, 2026. The company confirmed that there were no disagreements between Mr. Dworak and the company regarding its operations, policies, or practices. In response to this change, Jason A. Amello, currently the Chief Financial Officer, has been appointed as the principal accounting officer, also effective April 10, 2026. Mr. Amello will not receive any additional compensation for this additional role, and there will be no changes to his existing compensation plans or arrangements. This transition in leadership is part of the company's ongoing efforts to maintain effective financial oversight and governance as it continues to navigate its operational strategies in the biopharmaceutical sector.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.